Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q3 EPS by 11c; Issues Solid Oultook

November 5, 2013 4:12 PM

Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q3 EPS of $1.78, $0.11 better than the analyst estimate of $1.67. Revenue for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found